Searching News Database: Bipolar Disorder
HSMN NewsFeed - 28 Mar 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
HSMN NewsFeed - 15 Jul 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 9 Apr 2014
Brainsway's Deep TMS System Will be Exclusively Marketed by Medison Pharma in Israel
Brainsway's Deep TMS System Will be Exclusively Marketed by Medison Pharma in Israel
HSMN NewsFeed - 18 Feb 2014
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
HSMN NewsFeed - 21 Nov 2013
Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine
Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine
HSMN NewsFeed - 30 Jul 2013
Alexza Pharmaceuticals Announces European Launch of ADASUVE(R) (Staccato(R) Loxapine)
Alexza Pharmaceuticals Announces European Launch of ADASUVE(R) (Staccato(R) Loxapine)
HSMN NewsFeed - 21 Feb 2013
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
HSMN NewsFeed - 22 Aug 2012
Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodon(R)
Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodon(R)
HSMN NewsFeed - 10 Aug 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
HSMN NewsFeed - 10 Aug 2010
Labopharm announces U.S. launch of OLEPTRO(TM) for treatment of major depressive disorder in adults
Labopharm announces U.S. launch of OLEPTRO(TM) for treatment of major depressive disorder in adults
HSMN NewsFeed - 22 Jul 2010
Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
HSMN NewsFeed - 14 May 2010
Epizyme Appoints Mikel Moyer, Ph.D., Vice President of Molecular Discovery
Epizyme Appoints Mikel Moyer, Ph.D., Vice President of Molecular Discovery
HSMN NewsFeed - 11 Mar 2010
Illumina and Glenn Close Announce the First Full Coverage DNA Sequencing of a Named Female
Illumina and Glenn Close Announce the First Full Coverage DNA Sequencing of a Named Female
HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
HSMN NewsFeed - 11 May 2009
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
HSMN NewsFeed - 17 Mar 2009
Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
HSMN NewsFeed - 16 Mar 2009
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
HSMN NewsFeed - 29 Jan 2009
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
HSMN NewsFeed - 16 Sep 2008
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal(R)
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal(R)
HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
HSMN NewsFeed - 31 Jul 2008
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
HSMN NewsFeed - 30 Jul 2008
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
HSMN NewsFeed - 29 May 2008
Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
HSMN NewsFeed - 19 May 2008
Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
HSMN NewsFeed - 27 Feb 2008
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
HSMN NewsFeed - 25 Feb 2008
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
HSMN NewsFeed - 18 Jan 2008
Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States
Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States
HSMN NewsFeed - 26 Dec 2007
Noven Announces FDA Tentative Approval of Stavzor(TM) Valproic Acid Delayed Release Capsules
Noven Announces FDA Tentative Approval of Stavzor(TM) Valproic Acid Delayed Release Capsules
HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 23 Oct 2007
FDA Issues Approvable Letter for Stavzor(TM) Delayed Release Valproic Acid Capsules
FDA Issues Approvable Letter for Stavzor(TM) Delayed Release Valproic Acid Capsules
HSMN NewsFeed - 20 Sep 2007
Robert S. Fishman, MD, FCCP Joins Alexza as Vice President, Medical Affairs
Robert S. Fishman, MD, FCCP Joins Alexza as Vice President, Medical Affairs
HSMN NewsFeed - 11 Sep 2007
Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
HSMN NewsFeed - 21 Jun 2007
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
HSMN NewsFeed - 20 Mar 2007
Barr Confirms Filing an Application with a Paragraph IV Certification for ABILIFY(R) Tablets
Barr Confirms Filing an Application with a Paragraph IV Certification for ABILIFY(R) Tablets
HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
HSMN NewsFeed - 3 Jan 2007
D-Pharm Announces Positive Phase IIb Trial Results for DP-b99 in Acute Stroke Patients
D-Pharm Announces Positive Phase IIb Trial Results for DP-b99 in Acute Stroke Patients
HSMN NewsFeed - 18 Dec 2006
Statement from Eli Lilly and Company: Response to The New York Times Article from December 18, 2006
Statement from Eli Lilly and Company: Response to The New York Times Article from December 18, 2006
HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
Additional items found! 114
Members Archive contains
114 additional stories matching:
Bipolar Disorder
(Password required)
Bipolar Disorder
(Password required)